ARCHIVES

New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

Natural Product Drug Discovery Groups Receive Concept Approval

February 26, 1988

Kentucky Okays Cancer Commission, $1 Million Budget

April 21, 1978

In Brief: Adamson Takes Job at Soft Drink Association; Zack Hall to Direct Neurological Institute

August 12, 1994

Congress Provides 7% Increase For NIH, 6.6% for NCI, In FY98 Appropriation

November 14, 1997

PFS Is A Benefit “In The Right Context,” Pazdur Says In Q&A On Avastin Approval.

February 29, 2008

ICF Clement Joins Dynalectron In FCRF

January 9, 1987